Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paracelsian calls off launch of dietary supplements with HIV, cancer treatment claims.

This article was originally published in The Tan Sheet

Executive Summary

PARACELSIAN ANDROVIR, ANDROCAR NEAR-TERM COMMERCIALIZATION OPTIONS are being examined by the company after it received a letter from FDA stating that the agency would regard the products as unapproved drugs, the Ithaca, N.Y.-based company announced June 9. "The FDA has made it very clear that the company's plan to market AndroVir and AndroCar as dietary supplements, targeted respectively to the AIDS community and to cancer patients, would cause the FDA to classify these products as drugs, not dietary supplements," Paracelsian said. "Given the FDA's position, we have determined that it would not be economically viable to introduce these products as dietary supplements for the general population."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel